Aranesp

Lea en español

AranespAranesp is the trade name for Darbepoetin alfa, a synthetic version of erythropoietin, which stimulates the production of red blood cells. Aranesp has been used since its approval by the U.S. Food and Drug Administration (FDA) in 2001 to treat patients with anemia, as well as chronic renal failure. It has been frequently prescribed to individuals suffering anemia as a byproduct of chemotherapy.
The FDA has required black box warnings on all sales of Darbepoetin alfa in the United States, citing a number of potential adverse health risks, including:

  • Myocardial infarction, or heart attack, as well as congestive heart failure
    Hypertension (high blood pressure), with increased risk of stroke
  • Venous thromboembolism
  • Thrombosis of vascular access
  • Tumor progression or recurrence

If you experienced side effects after being prescribed Aranesp, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

Defective Drugs & Medical Devices Topics

Latest Articles

The 25th Amendment to the United States Constitution Is in the News

The Constitutional Process for Replacing a President Who Lacks Capacity to Serve The United States C…

15 Oct 2020, Thursday

The Legal Consequences of Voting Twice

Why You Shouldn’t Follow Trump’s Suggestion to “Test Integrity of Electoral System” | P…

21 Sep 2020, Monday

Medical Malpractice: How It Differs from Other Negligence Claims

The Standard of Care – What You Must Prove to Recover for Your Losses When you’re hurt in an…

21 Aug 2020, Friday